Rilonacept in the treatment of chronic inflammatory disorders

Drugs of Today

Volumn 45, Issue 6, 2009, Pages 423-430

  McDermott, Michael F ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT;

CINCA SYNDROME; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GOUT; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MUCKLE WELLS SYNDROME; REVIEW; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INFLAMMATION; RECEPTORS, INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS;

EID: 70350045050     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.6.1378935     Document Type: Review

References (47)

1. Auron, P.E., Webb, A.C., Rosenwasser, L.J. et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A 1984, 81(24): 7907-7911 (Pubitemid 15169171)
2. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27: 519-50.
3. Agostini, L., Martinon, F., Burns, K., McDermott, M.F., Hawkins, P.N., Tschopp, J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20(3): 319-325 (Pubitemid 38388233)
4. Martinon, F., Tschopp, J. Inflammatory caspases and inflammasomes: Master switches of inflammation. Cell Death Differ 2007, 14(1): 10-22. (Pubitemid 44911890)
5. Dinarello, C.A. Blocking IL-1 In systemic inflammation. J Exp Med 2005, 201(9): 1355-1359
6. Aksentijevich, I., Nowak, M., Mallah, M. et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem Inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002, 46(12): 3340-3348 (Pubitemid 35453546)
7. Hawkins, P.N., Lachmann, H.J., McDermott, M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348(25): 2583-2584
8. Church, L. D., Cook, G. P., McDermott M. F. Primer: Inflammasome and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008, 4(1): 34-42.
9. Kile, R. L., Rusk, H.A. A case of cold urticaria with an unusual family history. JAMA 1940, 114(12): 1067-1068
10. Muckle, T.J., Wells, M. Urticaria, deafness, and amyloidosis: A new heredo-familial syndrome. Q J Med 1962, 31: 235-248
11. Prieur, A.M., Griscelli, C., Lampert, F. et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987, 66: 57-68. (Pubitemid 18137140)
12. Hoffman, H.M. Hereditary immunologic disorders caused by pyrin and cryopyrin. Curr Allergy Asthma Rep 2007, 7(5): 323-330
13. Aksentijevich, I., D Putnam, C., Remmers, E.F. et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56(4): 1273-1285 (Pubitemid 46608652)
14. Hoffman, H.M., Mueller, J.L., Broide, D.H., Wanderer, A.A., Kolodner, R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29(3): 301-305
15. Dode, C., Le Du, N., Cuisset, L. et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: A novel mutation underlies both syndromes. Am J Hum Genet 2002, 70(6): 1498-1506 (Pubitemid 34533897)
16. Aganna, E., Martinon, F., Hawkins, P.N. et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002, 46(9): 2445-2452
17. Hawkins, P.N., Bybee, A., Aganna, E., McDermott, M.F. Response to anakinra in a de novo case of neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2004, 50(8): 2708-2709 (Pubitemid 39062735)
18. Hawkins, P.N., Lachmann, H.J., Aganna, E., McDermott, M.F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004, 50(2): 607-612 (Pubitemid 38198844)
19. Hoffman, H.M., Rosengren, S., Boyle, D.L. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364(9447): 1779-1785 (Pubitemid 39488063)
20. Goldbach-Mansky, R., Dailey, N.J., Canna, S.W. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006, 355(6): 581-592 (Pubitemid 44200651)
21. Leslie, K.S., Lachmann, H.J., Bruning, E. et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006, 142(12): 1591-1597 (Pubitemid 44969215)
22. Maksimovic, L., Stirnemann, J., Caux, F. et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 2008, 47(3): 309-310
23. Mirault, T., Launay, D., Cuisset, L. et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006, 54(5): 1697-1700
24. O'Connell, S.M., O'Regan, G.M., Bolger, T. et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007, 24(1): 85-89 (Pubitemid 46245630)
25. Ross, J.B., Finlayson, L.A., Klotz, P.J. et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008, 12(1): 8-16.
26. Rynne, M., Maclean, C., Bybee, A., McDermott, M.F., Emery, P. Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann Rheum Dis 2006, 65(4): 533-534
27. Mathews, R.J., Sprakes, M., Hamlin, P.J., McDermott. M.F. NOD-like receptors and inflammation. Arthritis Res Ther 2008, 10(6): 228.
28. Church, L.D., McDermott, M. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009, 11(1): 81-89
29. Economides, A.N., Carpenter, L.R., Rudge, J.S. et al. Cytokine traps: Multi-component, high-affinity blockers of cytokine action. Nat Med 2003, 9(1): 47-52.
30. Dinarello, C.A. Setting the cytokine trap for autoimmunity. Nat Med 2003, 9(1): 20-22
31. Church, L.D., McDermott, M.F. Rilonacept in cryopyrin-associated periodic syndromes: The beginning of longer-acting interleukin-1 antagonism. Nat Clin Pract Rheumatol 2009, 5(1): 14-15
32. Martinon, F., Petriltl, V., Mayor, A., Tardivel, A., Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440(7081): 237-241 (Pubitemid 43372104)
33. Bendtzen, K., Mandrup-Poulsen, T., Nerup, J., Nielsen, J.H., Dinarello, C.A., Svenson, M. Cytotoxicity of human pl 7 interleukin-1 for pancreatic Islets of Langerhans. Science 1986, 232(4757): 1545-1547 (Pubitemid 16061563)
34. De Benedetti, F., Pignatti, P., Massa, M., Sartirana, P., Ravelli, A., Martini, A. Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995, 13(6): 779-784 (Pubitemid 3011445)
35. Wise, C.A., Gillum, J.D., Seidman, C.E. et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002, 11(8): 961-969
36. Ratner, M. IL-1 Trap go-ahead. Nat Biotechnol 2008, 26(5): 485.
37. Hoffman, H.M. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther 2009, 9(4): 519-531
38. Hoffman, H.M., Throne, M.L., Amar, N.J. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-ossociated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58(8): 2443-2452
39. Hoffman, H. M., Grimes, I. M., Weinstein, S.D. Long-term tafety of rilonacept (IL-1 Trap) in cryopyrin-associated periodic syndromes (CAPS): Results from a 1-year study. Clin Exp Rheumatol 2008, 26(2): 205-6. Fifth International Congr on Familial Mediterranean Fever and Systemic Autoinflammatory Diseases (April 4-8, Rome) 2008, Abst O13.
40. Goldbach-Mansky, R., Shroff, S.D., Wilson, M. et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008, 58(8): 2432-2442
41. Hashkes, P., Lovell, D., Giannini, E., Huang, B., Kastner, D. Rilonacept (IL-1 Trap) for treatment of colchicine resistant familial Mediterranean fever: A randomized, multicenter double-blinded, alternating treatment (N of 1) trial. Clin Exp Rheumatol 2008, 26(2): 193.
42. Terkeltaub, R., Schumacher, H.R., Sundy, J. et al. Placebo-controlled pilot study of rilonacept (IL-1 Trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Arthritis Rheum [71st Annu Meet Am Coll Rheumatol (Nov 6-11, Boston) 2007] 2007, 56(12): 4231-4232, Abst L2.
43. Radin, A., Terkeltaub, R., Schumacher, H. et al. Placebo-controlled pilot study of rilonacept (IL-1 Trap), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Clinical and Experimental Rheumatology 2008, 26(2): G5.
44. Lovell, D., Giannini, E., Kimura, Y. et al. Preliminary evidence for bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis. Annu Eur Congr Rheumatol (EULAR) (June 21-24, Amsterdam) 2006, Abst LB0005.
45. Lovell, D.J., Giannini, E.H., Kimura, Y. et al. Preliminary evidence for bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, In systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum [70th Annu Sci Meet Am Coll Rheumatol (Nov 10-15, Washington, D.C.) 2006] 2006, 54(9, Suppl.): Abst 718.
46. Rilonacept [IL-1 Trap, Arcalyst; Regeneron Pharmaceuticals] has reduced the Incidence of gout flares in a phase II study. Inpharma 2008, 1(1655); 9-9(1).
47. http://clinicaltrials.gov/ct2/show/NCT00582907.